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SUMMARY 
Following a request from the European Commission, EFSA was asked to review the scientific 
comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) on the scientific substantiation of a health claim related to beta-palmitate and 
increased calcium absorption pursuant to Article 14 of Regulation (EC) No 1924/2006. 
Comments submitted to EFSA via the European Commission Services originated from the applicant 
(IDACE). 
EFSA has reviewed the comments and shared them with the chair of the NDA Panel, Prof. Albert 
Flynn, and the chair of the NDA Working Group on Claims, Prof. Sean (J.J.) Strain.  
In its opinion adopted on 30 June 2011, the EFSA Panel on Dietetic Products, Nutrition and Allergies 
(NDA) concluded that the evidence provided was insufficient to establish a cause and effect 
relationship between the consumption of beta-palmitate and an increase in calcium absorption. The 
comments received do not change the conclusions of the NDA Panel. 
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1  On request from the European Commission, Question No EFSA-Q-2011-01081, issued on 30 November 2011. 
2  Correspondence: nda@efsa.europa.eu  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Article 16(6) of Regulation (EC) No 1924/2006 on nutrition and health claims states that: “The 
Authority, in accordance with Article 38(1) of Regulation (EC) No 178/2002, shall make its opinion 
public. The applicant or members of the public may make comments to the Commission within 
30 days from such publication.” 
The Regulation does not foresee a consultation on the EFSA opinion. It does, however, allow for the 
applicant or members of the public to make comments to the Commission relating to the EFSA 
opinion. The Commission’s services have established a practice for handling the comments provided 
by applicants and members of the public in order to allow their full consideration by the regulators in 
the health claims' authorisation process. More particularly, whenever the comments relate to the 
scientific assessment, they are transmitted to EFSA for consideration. The Commission and the 
Member States await the EFSA response to the comments before proceeding with the final discussion 
and the vote in the Standing Committee on the Food Chain and Animal Health on the draft measure 
authorising or rejecting the health claims for which comments were made. 
The procedure briefly outlined above is in line with the procedure foreseen in Article 31 of Regulation 
(EC) No 178/2002, whereby the Authority may be requested by the Commission to provide scientific 
or technical assistance in any field within its mission, and when the matter does not require scientific 
evaluation by a Scientific Committee or a Scientific Panel. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Commission requests EFSA, within the framework of scientific and technical assistance to the 
Commission foreseen in Article 31 of Regulation (EC) No 178/2002, to evaluate the comments of a 
scientific nature received by the Commission pursuant to Article 16(6) of Regulation (EC) 
No 1924/2006 and to provide the Commission with a response. 
Relevant actions performed under this mandate will be carried out in good cooperation between the 
Commission and EFSA in accordance with the procedure set out in the Annex to the Mandate (to be 
found in the EFSA Register of Questions under the mandate number M-2011-0063). 
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CONSIDERATION 
1. Introduction 
On 30 June 2011, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) adopted a 
scientific opinion on the scientific substantiation of a health claim related to beta-palmitate and 
increased calcium absorption pursuant to Article 14 of Regulation (EC) No 1924/2006
4
 following an 
application for authorisation from IDACE submitted via the Competent Authority of France (Claims 
serial number: 0092_FR, EFSA-Q-2008-172). 
In accordance with Article 16 of Regulation (EC) 1924/2006, the applicants or members of the public 
may make comments to the European Commission on opinions published by the Authority pursuant to 
Articles 16 and 18 of the Regulation. On 14 September 2011, the European Commission requested 
EFSA to respond to the scientific comments received during the commenting period specified in 
Article 16 of the Regulation. Comments submitted to EFSA via the European Commission Services 
originated from the applicant (IDACE). 
EFSA has reviewed the comments and shared them with the chair of the NDA Panel, Prof. Albert 
Flynn, and the chair of the NDA Working Group on Claims, Prof. Sean (J.J.) Strain. 
2. Comments related to the use of faecal calcium excretion as a proxy for calcium 
absorption 
The claimed effect identified in the application and evaluated by the Panel, and which might be a 
beneficial physiological effect for the target population for which the claim is intended (i.e. infants 
from birth to 12 months of age), was an increase in calcium absorption.  
The comments received relate to the use of faecal calcium excretion as a proxy for calcium absorption 
in five of the studies provided by the applicant (Carnielli et al., 1995, 1996; Kennedy et al., 1999; 
Lopez-Lopez et al., 2001; Lucas et al., 1997).  
Of these, three (Carnielli et al., 1995, 1996; Lucas et al., 1997) were balance studies which addressed 
the effects of beta-palmitate on calcium absorption. Two of them (Carnielli et al., 1995, 1996) also 
assessed faecal calcium excretion, whereas one (Lucas et al., 1997) investigated faecal excretion of 
fatty acid soaps relative to fat intake. The fourth study (Lopez-Lopez et al., 2001) investigated the 
effect of beta-palmitate on calcium content in faeces but did not address calcium absorption and did 
not report on calcium intake. The study by Kennedy et al. (1999) did not address calcium absorption 
or faecal calcium excretion.  
One small study (nine subjects per group, Carnielli et al., 1996) showed a statistically significant effect 
of beta-palmitate on calcium absorption which was associated with a statistically significant decrease 
in faecal fat excretion and faecal calcium excretion. However, a significant effect of beta-palmitate on 
calcium absorption was not observed in two studies (Carnielli et al., 1995; Lucas et al., 1997) 
compared to the control formula, despite a significant decrease in faecal excretion of calcium 
(Carnielli et al., 1995) or of fat (Lucas et al., 1997). The Panel considered that while there was 
evidence to support the biological plausibility of a proposed mechanism by which beta-palmitate could 
exert the claimed effect, two out of three studies did not find an effect of beta palmitate on calcium 
absorption.  
The comments received did not provide further evidence which would warrant a re-evaluation of these 
studies. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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3. Comments related to the use of bone mineral density (BMD) and bone mineral content 
(BMC) in infants as a proxy for calcium absorption 
The comments received also related to the use of bone mineral density (BMD) and bone mineral 
content (BMC) in infants as a proxy for calcium absorption in relation to one study (Kennedy et al., 
1999) provided for the scientific substantiation of the claim. 
The Panel notes in the Opinion that owing to limitations in the study design it could not be established 
that a higher BMC and BMD at three months of age in a sub-sample of the beta-palmitate group could 
be attributed to better calcium absorption. The Panel also notes that the evidence provided does not 
establish that a single measurement of BMC and BMD at the age of three months can be generally 
used as a proxy for the estimation of overall calcium absorption from birth as no baseline 
measurement was taken. The additional references quoted by the applicant address the effects of 
calcium from different sources on calcium absorption and bone mineral density in adults, or in post-
menopausal or elderly women (Heaney, 2006; Schuette and Knowles, 1988), or whether calcium 
deposition in bone and its subsequent metabolism could be used as an indirect long-term assessment of 
calcium utilization or bioavailability (Fairweather-Tait and Teucher, 2002), but do not provide 
additional information about the use of a single BMC and BMD measurement at the age of three 
months as a proxy for calcium absorption. 
The comments received did not provide further evidence which would warrant a re-evaluation of the 
study. 
CONCLUSIONS 
In its opinion adopted on 30 June 2011, the EFSA Panel on Dietetic Products, Nutrition and Allergies 
(NDA) concluded that the evidence provided was insufficient to establish a cause and effect 
relationship between the consumption of beta-palmitate and an increase in calcium absorption. The 
comments received do not change the conclusions of the NDA Panel. 
DOCUMENTATION PROVIDED TO EFSA 
Comments submitted to the European Commission by IDACE. 
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GLOSSARY/ABBREVIATIONS 
BMC  Bone mineral content 
BMD  Bone mineral density 
 
 
